ArticleCancer chemotherapy and pharmacology2025

A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results.

Jayesh Desai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.